Warning (512): /home/pharma/website/current/cakephp/app/pharmalicensing/tmp/cache/ is not writable [CORE/cake/libs/cache/file.php, line 267]
Code
        if ($this->_init && !is_writable($this->settings['path'])) {
            $this->_init = false;
            trigger_error(sprintf(__('%s is not writable', true), $this->settings['path']), E_USER_WARNING);
FileEngine::__active() - CORE/cake/libs/cache/file.php, line 267
FileEngine::init() - CORE/cake/libs/cache/file.php, line 94
Cache::_buildEngine() - CORE/cake/libs/cache.php, line 151
Cache::config() - CORE/cake/libs/cache.php, line 126
include - /home/pharma/website/releases/20120317114903/cakephp/app/pharmalicensing/config/core.php, line 345
Configure::__loadBootstrap() - CORE/cake/libs/configure.php, line 391
Configure::getInstance() - CORE/cake/libs/configure.php, line 52
include - CORE/cake/bootstrap.php, line 38
[main] - /home/pharma/website/releases/20120317114903/cakephp/webroot/pharmalicensing/index.php, line 100

• Home
• Licensing Center
  • Data Center
    • Out-licensing
    • In-licensing
    • Companies
    • Services
  • Reports
  • Newsletter
    • Subscribe
    • Partnering Update
    • Key Reports
    • Pharmalicensing Recommends
  • Pharmalicensing Intelligence
    • Industry News
    • Deals Review
    • Press Releases
    • Articles
  • Profiled Companies
  • Events
• Our Services
  • Partnering Search
  • Company Profiling
  • Reports
  • Pharma Transfer
  • Deal Negotiation
  • Pharmalicensing Intelligence
• About us
  • Case Studies
  • Our Audience
  • FAQ
  • Directions
  • MedicalDeviceLicensing.com
  • Innovaro Corporate
• Contact us

Login    Register

Search

Industry news

• Industry news
• Hematology
• News

YM BioSciences granted Orphan Drug Designation for CYT387

In order to access this content you must be logged in and have a subscription to Pharmalicensing Intelligence.

Pharmalicensing Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.

Subscribe now for instant access to the benefits Pharmalicensing Intelligence has to offer. Find out more.

Request a demo of
Pharmalicensing Intelligence

Related reports

Market Research Reports provided by reports.innovaro.com

Myelofibrosis - Pipeline Review, Q1 2011

Mar 2011 - 40 pages - $500

YM BioSciences Inc. – Product Pipeline Review – Q4 2010

Dec 2010 - 86 pages - $500

Orphan Drug Trends 2011

Nov 2011 - 97 pages - $5,700

Essential Thrombocythemia - Pipeline Review, Q3 2011

Jul 2011 - 82 pages - $500

Opportunities in Orphan Drugs

Jan 2010 - 107 pages - $3,835

Orphan Drug Strategies

Oct 2009 - 75 pages - $3,800

Pharmalink AB - Product Pipeline Review - Q4 2010

Nov 2010 - 31 pages - $500

Thrombocythaemia Myelofibrosis - Pipeline Review, Q2 2011

May 2011 - 42 pages - $500

Allos Therapeutics, Inc (ALTH) - Financial and Strategic SWOT Analysis Review

May 2011 - 38 pages - $125

Lysosomal Disease - Pipeline Review, Q4 2010

Dec 2010 - 34 pages - $500

More Related Market Research Reports >>>

Related news

Latest News

Bayer

Rivaroxaban Successfully Demonstrated Non-Inferiority Compared to Standard of Care for the Prevention of Recurrent Venous Thromboembolism in Pivotal Phase 3 Study

YM BioSciences granted Orphan Drug Designation for CYT387

YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study

Affymax and Takeda Announce Preliminary U.S. Registration Strategy for Investigational Drug, Hematide(TM)/Peginesatide, to Treat Anemia in Chronic Renal Failure

The Gamida Cell-TEVA Joint Venture Receives FDA Fast Track Designation for StemEx

More news... | RSS Feed...

Most Viewed

Rivaroxaban Successfully Demonstrated Non-Inferiority Compared to Standard of Care for the Prevention of Recurrent Venous Thromboembolism in Pivotal Phase 3 Study

Bayer

Affymax and Takeda Announce Preliminary U.S. Registration Strategy for Investigational Drug, Hematide(TM)/Peginesatide, to Treat Anemia in Chronic Renal Failure

YM BioSciences granted Orphan Drug Designation for CYT387

YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study

The Gamida Cell-TEVA Joint Venture Receives FDA Fast Track Designation for StemEx

Therapeutic Target

Cardiovascular

Dermatology

Endocrine and Metabolic

Gastroenterology

Genitourinary

Hematology

Immunology and Allergy

Infection

Musculoskeletal

Neurology

Obstetrics and Gynecology

Oncology

Ophthalmology

Psychiatry

Pulmonary

Categories

Deals and Alliances

Development

Financial Results

Financings

Intellectual Property

Regulatory

Press releases

Deals review

Headlines

PR Newswire

Products:	Partnering Search	Company Profiling	Pharmalicensing Intelligence	Reports	Comparision
In-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Out-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Companies:	Profiled companies	Industry Sector	Therapeutic Target	Geographic Location	Search	Add your company
Reports:	Biotechnology	Business Development	Management	Market & Sales	Medical Devices	Pharmaceuticals
News:	Deals & Alliances	Development	Financial Results	Financings	Intellectual Property	Regulatory
Events:	Pharma events	Calendar	Organizers	Featured events	Search
Articles:	Industrial Sector	Therapeutic Target	Articles date
Deals:	Industry Sector	Therapeutic Target	Deals Date	Search	Reports	Press releases
About us:	Our Audience	Case Studies	Newsletter	FAQ	Contact us	Site map

© Copyright 1998-2012 Innovaro Europe Ltd All rights reserved. Terms and Conditions | Contact us